The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro

Endocrinology

Volumn 144, Issue 11, 2003, Pages 5105-5117

  Gee, J M W ^a   Harper, M E ^a   Hutcheson, I R ^a   Madden, T A ^a   Barrow, D ^a   Knowlden, J M ^a   McClelland, R A ^a   Jordan, N ^a   Wakeling, A E ^b   Nicholson, R I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ESTROGEN RECEPTOR; FULVESTRANT; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN BCL 2; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE; CELL SELECTION; CELL STRAIN MCF 7; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; HORMONE INHIBITION; HORMONE RESPONSE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DRUG COMBINATIONS; DRUG RESISTANCE; DRUG SYNERGISM; EPIDERMAL GROWTH FACTOR; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 0242721012     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-0705     Document Type: Article

References (61)

1. Nicholson RI 1993 Recent advances in the anti-hormonal therapy of breast cancer. Curr Opin Invest Drugs 2:1259-1268
2. Baum M 1997 Tamoxifen. Endocr Relat Cancer 4:237-243
3. Kenny FS, Willsher PC, Gee JM, Nicholson R, Pinder SE, Ellis IO, Robertson JF 2001 Change in expression of ER, Bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer. Breast Cancer Res Treat 65:135-144
4. Dowsett M 1996 Endocrine resistance in advanced breast cancer. Acta Oncol 35:91-95
5. Burgering BM, Coffer PJ 1995 Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376:599-602
6. Wells A 1999 EGF receptor. Int J Biochem Cell Biol 31:637-643
7. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME 1995 Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326-1331
8. Franke TF, Kaplan DR, Cantley LC 1997 PI3K: downstream AKTion blocks apoptosis. Cell 88:435-437
9. Gibson S, Tu S, Oyer R, Anderson SM, Johnson GL 1999 Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem 274:17612-17618
10. Kitagawa D, Tanemura S, Ohata S, Shimizu N, Seo J, Nishitai G, Watanabe T, Nakagawa K, Kishimoto H, Wada T, Tezuka T, Yamamoto T, Nishina H, Katada T 2002 Activation of extracellular signal-regulated kinase by ultraviolet is mediated through Src-dependent epidermal growth factor receptor phosphorylation. Its implication in an anti-apoptotic function. J Biol Chem 277: 366-371
11. Nicholson RI, Gee JM, Harper ME 2001 EGFR and cancer prognosis. Eur J Cancer 37:9-15
12. Klijn JG, Look MP, Portengen H, Alexieva-Figusch J, van Putten WL, Foekens JA 1994 The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat 29:73-83
13. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO, Blamey RW 1994 Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29:117-125
14. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO, Blamey RW 1994 Transforming growth factor-α and endocrine sensitivity in breast cancer. Cancer Res 54:1684-1689
15. Gee JM, Robertson JF, Ellis IO, Nicholson RI 2001 Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95:247-254
16. Perez-Tenorio G, Stal O 2002 Southeast Sweden Breast Cancer Group: activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86:540-545
17. van Agthoven T, van Agthoven TL, Portengen H, Foekens JA, Dorssers LC 1992 Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 52:5082-5088
18. Miller DL, el-Ashry D, Cheville AL, Liu Y, McLeskey SW, Kern FG 1994 Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ 5:1263-1274
19. Vickers PJ, Dickson RB, Shoemaker R, Cowan KH 1988 A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol 2:886-892
20. Long B, McKibben BM, Lynch M, van den Berg HW 1992 Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. Br J Cancer 65:865-869
21. van Agthoven T, van Agthoven TL, Dekker A, Foekens JA, Dorssers LC 1994 Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations. Mol Endocrinol 8:1474-1483
22. van den Berg HW, Claffie D, Boylan M, McKillen J, Lynch M, McKibben B 1996 Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression. Br J Cancer 73:477-481
23. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM 2001 Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 8:175-182
24. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044
25. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM, Nicholson RI 2001 Enhanced epidermal growth factor receptor signalling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex). Endocrinology 142: 2776-2788
26. Ranson M 2002 ZD1839 (Iressa): for more than just non-small cell lung cancer. Oncologist 7:16-24
27. Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR, Cartlidge SA, Woodburn JR 1996 Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat 38:67-73
28. Jones HE, Barrow D, Dutkowski CM, Goddard L, Smith C, Harper ME, Nicholson RI 2001 Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways. Prostate 49:38-47
29. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL 2001 Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895
30. Vindelov LL, Christensen IBJ 1993 An integrated set of methods for routine flow cytometric DNA analysis. In: Darzynkiewicz Z, Crissman HA, eds. Methods in cell biology: flow cytometry. Vol 33. London: Academic Press; 127-137
31. Green DR, Reed JC 1998 Mitochondria and apoptosis. Science 281:1309-1312
32. Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW, Nicholson RI 1994 Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628
33. Gee JM, Douglas-Jones A, Hepburn P, Sharma AK, McClelland RA, Ellis IO, Nicholson RI 1995 A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers. J Pathol 177:285-293
34. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J 2002 Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124
35. Beerli RR, Hynes NE 1996 Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem 271:6071-6076
36. Sutherland RL, Green MD, Hall RE, Reddel RR, Taylor IW 1983 Tamoxifen induces accumulation of MCF-7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol 19:615-621
37. Danova M, Pellicciari C, Zibera C, Mangiarotti R, Gibelli N, Giordano M, Wang E, Mazzini G, Riccardi A 1993 Cell cycle kinetic effects of tamoxifen on human breast cancer cells. Flow cytometric analyses of DNA content, BrdU labeling, Ki-67, PCNA, and statin expression. Ann NY Acad Sci 698:174-181
38. Johnston SR, Boeddinghaus IM, Riddler S, Haynes BP, Hardcastle IR, Rowlands M, Grimshaw R, Jarman M, Dowsett M 1999 Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Cancer Res 59:3646-3651
39. Zhang GJ, Kimijima I, Onda M, Kanno M, Sato H, Watanabe T, Tsuchiya A, Abe R, Takenoshita S 1999 Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels. Clin Cancer Res 5:2971-2977
40. Arteaga CL, Coronado E, Osborne CK 1988 Blockade of the epidermal growth factor receptor inhibits transforming growth factor α-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol Endocrinol 2:1064-1069
41. Guvakova MA, Surmacz E 1997 Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 57:2606-2610
42. deFazio A, Chiew YE, McEvoy M, Watts CK, Sutherland RL 1997 Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells. Cell Growth Differ 8:903-911
43. Yarden RI, Wilson MA, Chrysogelos SA 2001 Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem 81:232-246
44. Wilson MA, Chrysogelos SA 2002 Identification and characterisation of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells. J Cell Biochem 85: 601-614
45. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H 2001 Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J Biol Chem 276:9817-9824
46. Donovan JC, Milic A, Slingerland JM 2001 Constitutive MEK/MAPK activation leads to p27 (Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 276:40888-40895
47. Wakeling AE, Nicholson RI, Gee JM 2001 Prospects for combining hormonal and nonhormonal growth factor inhibition. Clin Cancer Res 12(Suppl):4350-4355
48. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME 1999 Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286:1358-1362
49. Stambolic V, Mak TW, Woodgett JR 1999 Modulation of cellular apoptotic potential: contributions to oncogenesis. Oncogene 18:6094-6103
50. Huang SM, Bock JM, Harari PM 1999 Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935-1940
51. Wang ZH, Ding MX, Yuan JP, Jin ML, Hao CF, Chew-Cheng SB, Ng HK, Chew EC 1999 Expression of bcl-2 and Bax in EGFR-antisense transfected and untransfected glioblastoma cells. Anticancer Res 19:4167-4170
52. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, Ciardiello F 2002 Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8:3250-3258
53. Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, Bianco AR, Tortora G 2002 ZD1839 ('Iressa'), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 98:463-469
54. Gajewski TF, Thompson CB 1996 Apoptosis meets signal transduction: elimination of a BAD influence. Cell 87:589-592
55. Massarweh S, Shou J, Mohsin SK, Ge M, Wakeling AE, Osborne CK, Schiff R 2002 Inhibition of epidermal growth factor/HER2 receptor signalling using ZD1839 ("Iressa") restores tamoxifen sensitivity and delays resistance to oestrogen deprivation in HER2-overexpressing breast tumours. Proc Am Soc Clin Oncol 21:33 (Abstract)
56. Sirotnak FM, She Y, Lee F, Chen J, Scher HI 2002 Studies with CWR22 Xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 8:3870-3876
57. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG 2000 Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885-4892
58. Gee JM, Nicholson RI 2003 Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization. Breast Cancer Res 5: 126-129
59. Albain K, Elledge R, Gradishar WJ, Hayes DF, Rowinsky E, Hudis C, Pusztai L, Tripathy D, Modi S, Rubi S 2002 Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 76:20 (Abstract)
60. Robertson JFR, Gutteridge E, Cheung KL, Owers R, Koehler M, Hamilton L 2002 A phase II study of ZD1839 ('Iressa') in tamoxifen-resistant ER-positive and endocrine insensitive (ER-negative) breast cancer. Breast Cancer Res Treat 76:357 (Abstract)
61. Herbst RS 2002 ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs 11:837-849